Project Grant HT94252510750
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37232, USA
Similar Awards
This federal Project Grant award of $2,399,874.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research by Vanderbilt University Medical Center (VUMC) to investigate the molecular basis of post-injury syndromes and mineralization disorders. The research aims to transform healthcare for military service members, veterans, and the broader public. The 4-year award, which commenced on August 1, 2025, will fund a diverse...
This $1,211,469 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports a therapeutic intervention research project to reverse gastric precancer conducted by Vanderbilt University Medical Center (VUMC). The award, with a performance period from June 1, 2024 to May 31, 2028, will enable VUMC to leverage its clinical expertise and research capabilities to advance medical knowledge and improve patient care. As a leading...
The U.S. Department of Defense's Defense Health Agency awarded a $1,317,028 Project Grant to Vanderbilt University Medical Center (VUMC) with a period of performance from June 1, 2024 to May 31, 2028. The grant, under CFDA 12.420 - Military Medical Research and Development program, will support VUMC's research into therapeutic interventions to reverse gastric precancer. As a leading academic medical center and biomedical research institution, VUMC will leverage its clinical expertise and...
The U.S. Defense Health Agency awarded a $1,213,276 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2023 through August 31, 2026, will fund research on the role of vascular mimicry in the outgrowth of dormant melanoma micrometastases. The goal of this research is to transform health care for Service Members and the American public through innovative and impactful medical research on solutions...
The federal Cooperative Agreement award, issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, provides $5,665,088.00 in funding to Vanderbilt University Medical Center (VUMC) to support the "CONVERGENT SCIENCE CANCER CONSORTIUM FOR IMMUNE CELL ENGINEERING" research project. The award period runs from August 1, 2025 to July 31, 2029. The project aims to advance biomedical research that can transform healthcare for military...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
The federal Project Grant award of $1,008,313 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. This award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award was granted to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution, to conduct research on melanoma....
The Department of the Army Medical Command awarded Vanderbilt University Medical Center (VUMC) a $1,310,914 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on monitoring peripheral immunity to chemotherapy and immunotherapy in breast cancer. The 3-year award, which began on February 1, 2024, aims to advance the understanding of biomarkers and identify novel therapies for breast cancer treatment. As a leading academic medical center with...
This Cooperative Agreement award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,400,000.00 to Vanderbilt University Medical Center (VUMC) to support the Kidney Cancer Clinical Trials Consortium. The award commenced on September 15, 2024 and will run through September 14, 2028. Through this funding, VUMC will conduct advanced biomedical research and clinical trials focused on transforming healthcare for military service...
The Department of the Army Medical Command awarded Vanderbilt University a $1.6 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support research into Modulation of Lung and Bone Microenvironments to Treat Breast Metastases. The three-year award beginning September 15, 2022 will fund investigation into medical solutions for breast cancer that has metastasized to the lungs and bones. As part of the Military Medical Research and Development...